← All drugs
Drug · FAERS side-effect profile with label screen

Acetaminophen, Guaifenesin, and Phenylephrine… side effects: what 158,913 FDA adverse event reports show

Acetaminophen, Guaifenesin, And Phenylephrine Hydrochloride · 1,177 reaction terms · 878,120 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

158,913 reports · 59% serious · 12,074 with death outcome · 69% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Acetaminophen injection is indicated for • the management of mild to moderate pain in adult and pediatric patients 2 years and older • the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older • the reduction of fever in adult and pediatric patients.

FDA label, Indications and Usage

What it is

Paracetamol is a member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.

PubChem CID 1983 (ChEBI)

Boxed warning

RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 3Lab value / disease marker 11Not in label — unassessed 26
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,137 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Presbyacusis140108.2
86.5–135.5ROR 108.3 · calibrated p 9e-8 ✓
58.9 EB05 51.1 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=139 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Blood pressure diastolic abnormal1,09798.4
90.9–106.4ROR 99.0 · calibrated p 1e-7 ✓
56.2 EB05 53.5 · IC025 +5.7
3/3 methods agree
Lab value / disease markerserious n=1,021no trial arm names this drug
Blood pressure systolic abnormal97384.6
78.0–91.7ROR 85.1 · calibrated p 4e-7 ✓
51.5 EB05 48.8 · IC025 +5.5
3/3 methods agree
Lab value / disease markerserious n=907no trial arm names this drug
Subcutaneous drug absorption impaired17763.3
52.9–75.8ROR 63.4 · calibrated p 3e-6 ✓
42.6 EB05 37.6 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=175 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Neurologic neglect syndrome17358.8
49.1–70.3ROR 58.8 · calibrated p 6e-6 ✓
40.5 EB05 35.7 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=173 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
C-reactive protein21741.3
35.4–48.1ROR 41.3 · calibrated p 5e-5 ✓
31.4 EB05 28.1 · IC025 +4.7
3/3 methods agree
Lab value / disease markerserious n=217 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Deep vein thrombosis postoperative44838.9
35.0–43.2ROR 39.0 · calibrated p 6e-5 ✓
30.1 EB05 27.8 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=448 · ♀ 100% (drug 69%)no trial arm names this drug
Lupus vulgaris26637.8
33.0–43.3ROR 37.8 · calibrated p 8e-5 ✓
29.4 EB05 26.6 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=266 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
X-ray abnormal39236.9
33.0–41.3ROR 37.0 · calibrated p 9e-5 ✓
28.9 EB05 26.6 · IC025 +4.6
3/3 methods agree
Lab value / disease markerserious n=392 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Pleural thickening14936.7
30.6–44.0ROR 36.7 · calibrated p 1e-4 ✓
28.7 EB05 25.0 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=149 · 100% clinicianno trial arm names this drug
Adjustment disorder with depressed mood43836.4
32.8–40.5ROR 36.5 · calibrated p 9e-5 ✓
28.6 EB05 26.4 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=436 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Carotid artery thrombosis17634.1
28.9–40.2ROR 34.1 · calibrated p 1e-4 ✓
27.1 EB05 23.9 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=176 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Autism spectrum disorder1,12233.9
31.7–36.2ROR 34.1 · calibrated p 1e-4 ✓
27.0 EB05 25.7 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=1,121 · ♀ 37% (drug 69%) · 100% consumerno trial arm names this drug
Anti-cyclic citrullinated peptide antibody13232.3
26.7–39.1ROR 32.4 · calibrated p 2e-4 ✓
26.0 EB05 22.5 · IC025 +4.3
3/3 methods agree
Lab value / disease markerserious n=132 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive1,32330.0
28.3–31.9ROR 30.3 · calibrated p 3e-4 ✓
24.5 EB05 23.4 · IC025 +4.5
3/3 methods agree
Lab value / disease markerserious PRR 23.9 · ♀ 100% (drug 69%) · 95% clinicianno trial arm names this drug
Temperature regulation disorder40529.8
26.8–33.2ROR 29.9 · calibrated p 3e-4 ✓
24.4 EB05 22.5 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=401 · ♀ 100% (drug 69%)no trial arm names this drug
Pleural fibrosis18428.5
24.3–33.5ROR 28.5 · calibrated p 4e-4 ✓
23.5 EB05 20.8 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=184 · ♀ 100% (drug 69%)no trial arm names this drug
Duodenal ulcer perforation1,29728.1
26.5–29.9ROR 28.4 · calibrated p 4e-4 ✓
23.3 EB05 22.2 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious PRR 22.6 · ♀ 100% (drug 69%) · 94% clinicianno trial arm names this drug
Dislocation of vertebra39328.1
25.2–31.4ROR 28.2 · calibrated p 4e-4 ✓
23.3 EB05 21.4 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=393 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Folliculitis1,81227.9
26.5–29.4ROR 28.2 · calibrated p 4e-4 ✓
23.1 EB05 22.2 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious PRR 26.2 · ♀ 100% (drug 69%) · 93% clinicianno trial arm names this drug
Swollen joint count increased53126.9
24.5–29.5ROR 27.0 · calibrated p 5e-4 ✓
22.4 EB05 20.9 · IC025 +4.3
3/3 methods agree
Lab value / disease markerserious n=530 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Blood magnesium increased13222.4
18.6–27.0ROR 22.4 · calibrated p 0.001 ✓
19.2 EB05 16.6 · IC025 +3.9
3/3 methods agree
Lab value / disease markerserious n=129 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Rheumatic fever61721.6
19.8–23.5ROR 21.6 · calibrated p 0.001 ✓
18.6 EB05 17.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=617 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Adjustment disorder18121.1
18.0–24.7ROR 21.1 · calibrated p 0.002 ✓
18.3 EB05 16.1 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=180 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Helicobacter infection1,40420.9
19.8–22.1ROR 21.1 · calibrated p 0.002 ✓
18.2 EB05 17.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious PRR 18.6 · ♀ 100% (drug 69%) · 92% clinicianno trial arm names this drug
Rheumatoid factor positive78220.5
19.1–22.2ROR 20.6 · calibrated p 0.002 ✓
17.9 EB05 16.8 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious n=782 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Retinitis20918.8
16.2–21.7ROR 18.8 · calibrated p 0.003 ✓
16.5 EB05 14.7 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=209 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Hand deformity1,55917.7
16.8–18.7ROR 17.9 · calibrated p 0.003 ✓
15.7 EB05 15.1 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious PRR 16.5 · ♀ 100% (drug 69%)no trial arm names this drug
Chronic kidney disease-mineral and bone disorder12717.5
14.6–21.1ROR 17.5 · calibrated p 0.004 ✓
15.5 EB05 13.4 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=127 · ♀ 0% (drug 69%)no trial arm names this drug
C-reactive protein abnormal74517.2
16.0–18.6ROR 17.3 · calibrated p 0.004 ✓
15.3 EB05 14.4 · IC025 +3.8
3/3 methods agree
Lab value / disease markerserious n=743 · ♀ 100% (drug 69%) · 90% clinicianno trial arm names this drug
Pemphigus1,43117.0
16.1–18.0ROR 17.2 · calibrated p 0.004 ✓
15.2 EB05 14.5 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious PRR 14.8 · ♀ 97% (drug 69%) · 94% clinicianno trial arm names this drug
Facet joint syndrome36016.9
15.1–18.8ROR 16.9 · calibrated p 0.004 ✓
15.0 EB05 13.8 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=357 · ♀ 100% (drug 69%)no trial arm names this drug
Nephrogenic anaemia51516.2
14.8–17.8ROR 16.3 · calibrated p 0.005 ✓
14.5 EB05 13.5 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=515no trial arm names this drug
Hyperparathyroidism secondary27816.2
14.3–18.3ROR 16.2 · calibrated p 0.005 ✓
14.4 EB05 13.1 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=277no trial arm names this drug
Synovitis1,81814.7
14.0–15.4ROR 14.8 · calibrated p 0.007 ✓
13.3 EB05 12.8 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious PRR 13.5 · ♀ 95% (drug 69%)no trial arm names this drug
Bronchial secretion retention12714.6
12.2–17.6ROR 14.6 · calibrated p 0.008 ✓
13.2 EB05 11.3 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=126 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Blood pressure diastolic decreased74414.6
13.5–15.8ROR 14.7 · calibrated p 0.008 ✓
13.2 EB05 12.4 · IC025 +3.6
3/3 methods agree
Lab value / disease markerserious PRR 12.9no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Serious infection13,8662.42.4–2.4signal
Liver injury5,4012.42.3–2.4signal
Fall / fracture6,3402.22.2–2.3signal
Tendon disorder5812.01.9–2.2raised
Interstitial lung disease1,4132.01.9–2.1raised
Depression3,9441.91.8–1.9raised
Anaemia4,1311.81.8–1.9raised
Kidney injury6,1571.81.7–1.8raised
Gi bleeding2,4311.81.7–1.8raised
Opportunistic infection1,7251.71.6–1.8raised
Thrombocytopenia2,7001.61.6–1.7raised
Venous thromboembolism2,5771.61.5–1.6raised
Arrhythmia / qt2,1061.41.4–1.5raised
Hyponatraemia8181.31.3–1.4raised
Hyperglycaemia / diabetes3,3131.31.2–1.3raised
Pancreatitis7241.21.1–1.3raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Acetaminophen, Guaifenesin, and Phenylephrine… only as a background or rescue medication (NCT03472469, NCT04452344); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)17,2951.7
1.7–1.8ROR 1.8 · calibrated p 0.849
1.7 EB05 1.7 · IC025 +0.8Reporting / coding artifactage-adj. PRR 1.8 · serious PRR 2.4no trial arm names this drug
Fatigue (tiredness)16,6822.9
2.8–2.9ROR 3.1 · calibrated p 0.597
2.8 EB05 2.8 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.9 · serious PRR 3.7no trial arm names this drug
Headache13,5492.9
2.8–2.9ROR 3.1 · calibrated p 0.604
2.9 EB05 2.8 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 3.0 · serious PRR 3.8no trial arm names this drug
Pain13,2962.9
2.8–2.9ROR 3.1 · calibrated p 0.606
2.8 EB05 2.8 · IC025 +1.5
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 3.5 · serious PRR 3.4no trial arm names this drug
Nausea13,1992.2
2.2–2.3ROR 2.3 · calibrated p 0.885
2.2 EB05 2.2 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.3 · serious PRR 2.9no trial arm names this drug
Off label use (used outside approved label)12,4291.9
1.9–1.9ROR 2.0 · calibrated p 0.932
1.9 EB05 1.9 · IC025 +0.9Reporting / coding artifactage-adj. PRR 1.7 · serious PRR 2.6no trial arm names this drug
Diarrhoea (diarrhea)11,2662.3
2.3–2.4ROR 2.4 · calibrated p 0.841
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.3 · serious PRR 2.7no trial arm names this drug
Arthralgia (joint pain)10,3903.4
3.3–3.4ROR 3.5 · calibrated p 0.477
3.3 EB05 3.3 · IC025 +1.7
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.4 · serious PRR 4.6no trial arm names this drug
Dyspnoea (shortness of breath)10,1782.4
2.4–2.4ROR 2.5 · calibrated p 0.816
2.4 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 2.7no trial arm names this drug
Vomiting7,6572.2
2.1–2.2ROR 2.2 · calibrated p 0.936
2.2 EB05 2.1 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.2 · serious PRR 2.4no trial arm names this drug
Pyrexia (fever)7,5992.9
2.9–3.0ROR 3.0 · calibrated p 0.615
2.9 EB05 2.8 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.8 · serious PRR 3.0no trial arm names this drug
Rash7,5752.3
2.3–2.4ROR 2.4 · calibrated p 0.860
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 2.5 · serious PRR 3.7no trial arm names this drug
Dizziness7,5232.0
2.0–2.1ROR 2.1 · calibrated p 0.975
2.0 EB05 2.0 · IC025 +1.0Not in label — unassessedage-adj. PRR 2.1 · serious PRR 2.4no trial arm names this drug
Asthenia (weakness)7,4662.7
2.6–2.7ROR 2.7 · calibrated p 0.720
2.6 EB05 2.6 · IC025 +1.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.6 · serious PRR 2.9no trial arm names this drug
Pruritus (itching)6,7562.4
2.3–2.4ROR 2.4 · calibrated p 0.838
2.4 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 3.9no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Acetaminophen (paracetamol) ↔ Liver injury / hepatotoxicity.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Acetaminophen, Guaifenesin, and Phenylephrine…?

In FDA FAERS, the most frequently co-reported reaction terms for Acetaminophen, Guaifenesin, and Phenylephrine… are fatigue, headache, pain, nausea, diarrhoea, arthralgia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Acetaminophen, Guaifenesin, and Phenylephrine… have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.

Do FAERS signals prove that Acetaminophen, Guaifenesin, and Phenylephrine… causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.